Orogen Royalties Inc
🇺🇸United States
- Country
- 🇺🇸United States
- Ownership
- Public
- Established
- 2020-01-01
- Employees
- 10K
- Market Cap
- -
- Website
- http://www.organon.com
- Introduction
Organon & Co. is a science based global pharmaceutical company, which develops and delivers innovative health solutions through a portfolio of prescription therapies within women’s health, biosimilars and established brands. The company was founded on March 11, 2020, and is headquartered in Jersey City, NJ.
Montelukast Post-marketing Comparative Study With Theophyline Added to Inhaled Corticosteroid (0476-396)
- First Posted Date
- 2008-09-22
- Last Posted Date
- 2024-08-15
- Lead Sponsor
- Organon and Co
- Target Recruit Count
- 84
- Registration Number
- NCT00756418
Study of Losartan in Pediatric Patients With Hypertension (MK-0954-337)
- First Posted Date
- 2008-09-22
- Last Posted Date
- 2024-06-18
- Lead Sponsor
- Organon and Co
- Target Recruit Count
- 101
- Registration Number
- NCT00756938
The Singulair® add-on Study Effectiveness of Adding Montelukast to Inhaled Corticosteroids in Adult Subjects With Uncontrolled Asthma (0476-384)
- First Posted Date
- 2008-09-19
- Last Posted Date
- 2024-06-07
- Lead Sponsor
- Organon and Co
- Target Recruit Count
- 800
- Registration Number
- NCT00755794
Effectiveness and Safety of Once or Twice Daily Mometasone Nasal Spray Versus Amoxicillin Versus Placebo for Treatment of Acute Rhinosinusitis (Study P02683)
Phase 2
Completed
- Conditions
- Acute Rhinosinusitis
- Interventions
- First Posted Date
- 2008-09-11
- Last Posted Date
- 2024-08-15
- Lead Sponsor
- Organon and Co
- Target Recruit Count
- 981
- Registration Number
- NCT00750750
A Comparative Double-blind, Double-dummy Study of Desloratadine (DL) 5 mg Once Daily, Cetirizine 10 mg Once Daily, and Placebo Once Daily in Patients With Chronic Idiopathic Urticaria (Study P03736)
- First Posted Date
- 2008-09-11
- Last Posted Date
- 2024-08-15
- Lead Sponsor
- Organon and Co
- Target Recruit Count
- 149
- Registration Number
- NCT00751166
Effectiveness and Safety of Once or Twice Daily Mometasone Nasal Spray Versus Amoxicillin Versus Placebo for Treatment of Acute Rhinosinusitis (Phase 3 Study)(Study P02692)
Phase 3
Completed
- Conditions
- Acute Rhinosinusitis
- Interventions
- First Posted Date
- 2008-09-11
- Last Posted Date
- 2024-08-15
- Lead Sponsor
- Organon and Co
- Target Recruit Count
- 981
- Registration Number
- NCT00751075
A Comparative Double-Blind, Double- Dummy Study of Desloratadine (DL) 5 MG Once Daily, Cetirizine 10 MG Once Daily, and Placebo Once Daily in Patients With Chronic Idiopathic Urticaria (Study P03735)
- First Posted Date
- 2008-09-11
- Last Posted Date
- 2024-08-15
- Lead Sponsor
- Organon and Co
- Target Recruit Count
- 174
- Registration Number
- NCT00751218
Tibolone Endometrium Study (Study 32972)(P06470)
Phase 3
Completed
- Conditions
- Postmenopausal Women
- Interventions
- First Posted Date
- 2008-09-03
- Last Posted Date
- 2022-02-03
- Lead Sponsor
- Organon and Co
- Target Recruit Count
- 32
- Registration Number
- NCT00745108
SAALT: Subtracting Salt and Adding Losartan Trial (0954A-335)
Phase 3
Completed
- Conditions
- Hypertension
- Interventions
- Behavioral: Low Salt Diet
- First Posted Date
- 2008-08-22
- Last Posted Date
- 2024-05-16
- Lead Sponsor
- Organon and Co
- Target Recruit Count
- 992
- Registration Number
- NCT00739674
The Safety and Effectiveness of MK0476 (Montelukast) in Patients With Chronic Asthma (0476-388)
Phase 1
Completed
- Conditions
- Chronic Asthma
- First Posted Date
- 2008-08-21
- Last Posted Date
- 2024-05-09
- Lead Sponsor
- Organon and Co
- Target Recruit Count
- 68
- Registration Number
- NCT00739297